{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T03:03:29Z","timestamp":1791169409124,"version":"4.1.0"},"reference-count":26,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,11,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Chronic myeloid leukemia is effectively treated with imatinib, but reactivation of BCR-ABL frequently occurs through acquisition of kinase domain mutations. The additional approved ABL tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib, along with investigational TKIs such as ponatinib (AP24534) and DCC-2036, support the possibility that mutation-mediated resistance in chronic myeloid leukemia can be fully controlled; however, the molecular events underlying resistance in patients lacking BCR-ABL point mutations are largely unknown. We previously reported on an insertion\/truncation mutant, BCR-ABL35INS, in which structural integrity of the kinase domain is compromised and all ABL sequence beyond the kinase domain is eliminated. Although we speculated that BCR-ABL35INS is kinase-inactive, recent reports propose this mutant contributes to ABL TKI resistance. We present cell-based and biochemical evidence establishing that BCR-ABL35INS is kinase-inactive and does not contribute to TKI resistance, and we find that detection of BCR-ABL35INS does not consistently track with or explain resistance in clinical samples from chronic myeloid leukemia patients.<\/jats:p>","DOI":"10.1182\/blood-2011-05-349191","type":"journal-article","created":{"date-parts":[[2011,9,10]],"date-time":"2011-09-10T02:51:56Z","timestamp":1315623116000},"page":"5250-5254","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":41,"title":["The BCR-ABL35INS insertion\/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia"],"prefix":"10.1182","volume":"118","author":[{"given":"Thomas","family":"O'Hare","sequence":"first","affiliation":[{"name":"Division of Hematology and Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR;"},{"name":"Howard Hughes Medical Institute, Portland, OR;"},{"name":"Huntsman Cancer Institute, University of Utah, Salt Lake City, UT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Zabriskie","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR;"},{"name":"Howard Hughes Medical Institute, Portland, OR;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Eide","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR;"},{"name":"Howard Hughes Medical Institute, Portland, OR;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupriya","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren T.","family":"Adrian","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR;"},{"name":"Howard Hughes Medical Institute, Portland, OR;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihong","family":"You","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amie S.","family":"Corbin","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Oregon Health & Science University, Portland, OR;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Press","sequence":"additional","affiliation":[{"name":"Department of Pathology, Oregon Health & Science University, Portland, OR;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor M.","family":"Rivera","sequence":"additional","affiliation":[{"name":"ARIAD Pharmaceuticals, Inc, Cambridge, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Toplin","sequence":"additional","affiliation":[{"name":"MolecularMD Corporation, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Wong","sequence":"additional","affiliation":[{"name":"MolecularMD Corporation, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Deininger","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute, University of Utah, Salt Lake City, UT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Druker","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR;"},{"name":"Howard Hughes Medical Institute, Portland, OR;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"11","key":"2019111808145209200_B1","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"23","key":"2019111808145209200_B2","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"5682","key":"2019111808145209200_B3","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor.","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"issue":"2","key":"2019111808145209200_B4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of wild-type and mutant Bcr-Abl.","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"issue":"11","key":"2019111808145209200_B5","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res"},{"issue":"5","key":"2019111808145209200_B6","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"issue":"4","key":"2019111808145209200_B7","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.ccr.2011.03.003","article-title":"Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036.","volume":"19","author":"Chan","year":"2011","journal-title":"Cancer Cell"},{"issue":"9","key":"2019111808145209200_B8","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1158\/0008-5472.CAN-10-3224","article-title":"The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.","volume":"71","author":"Eide","year":"2011","journal-title":"Cancer Res"},{"issue":"1","key":"2019111808145209200_B9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000210060","article-title":"BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors.","volume":"121","author":"Ma","year":"2009","journal-title":"Acta Haematol"},{"issue":"2","key":"2019111808145209200_B10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2353\/jmoldx.2008.070128","article-title":"An intron-derived insertion\/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy.","volume":"10","author":"Laudadio","year":"2008","journal-title":"J Mol Diagn"},{"issue":"4","key":"2019111808145209200_B11","first-page":"415","article-title":"Characterization of a novel frame shift mutation in BCR-ABL transcripts.","volume":"6","author":"Quigley","year":"2004","journal-title":"J Mol Diagn"},{"issue":"10","key":"2019111808145209200_B12","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1056\/NEJMc061882","article-title":"Dasatinib in chronic myelogenous leukemia.","volume":"355","author":"Chu","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111808145209200_B13","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/leu.2008.65","article-title":"Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia.","volume":"22","author":"Sherbenou","year":"2008","journal-title":"Leukemia"},{"issue":"12","key":"2019111808145209200_B14","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1158\/1535-7163.MCT-08-0482","article-title":"BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations.","volume":"7","author":"Lee","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"2019111808145209200_B15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1097-2765(03)00274-0","article-title":"Autoinhibition of Bcr-Abl through its SH3 domain.","volume":"12","author":"Smith","year":"2003","journal-title":"Mol Cell"},{"issue":"18","key":"2019111808145209200_B16","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1182\/blood-2010-02-269233","article-title":"Successful treatment using omacetaxine for a patient with CML and BCR-ABL1 [corrected] 35INS [published correction appears in Blood. 2010;116:1017].","volume":"115","author":"Mahadeo","year":"2010","journal-title":"Blood"},{"issue":"7","key":"2019111808145209200_B17","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/leu.2009.66","article-title":"Functional characterization of an activating TEK mutation in acute myeloid leukemia: a cellular context-dependent activating mutation.","volume":"23","author":"Tyner","year":"2009","journal-title":"Leukemia"},{"issue":"5486","key":"2019111808145209200_B18","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase.","volume":"289","author":"Schindler","year":"2000","journal-title":"Science"},{"issue":"35","key":"2019111808145209200_B19","doi-asserted-by":"crossref","first-page":"32214","DOI":"10.1074\/jbc.M111525200","article-title":"Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571.","volume":"277","author":"Corbin","year":"2002","journal-title":"J Biol Chem"},{"issue":"6","key":"2019111808145209200_B20","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.molcel.2006.01.035","article-title":"Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase.","volume":"21","author":"Nagar","year":"2006","journal-title":"Mol Cell"},{"issue":"1","key":"2019111808145209200_B21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrm1280","article-title":"Regulation of the c-Abl and Bcr-Abl tyrosine kinases.","volume":"5","author":"Hantschel","year":"2004","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"2019111808145209200_B22","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0092-8674(03)00194-6","article-title":"Structural basis for the autoinhibition of c-Abl tyrosine kinase.","volume":"112","author":"Nagar","year":"2003","journal-title":"Cell"},{"issue":"6","key":"2019111808145209200_B23","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0092-8674(03)00191-0","article-title":"A myristoyl\/phosphotyrosine switch regulates c-Abl.","volume":"112","author":"Hantschel","year":"2003","journal-title":"Cell"},{"issue":"3","key":"2019111808145209200_B24","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1158\/1535-7163.MCT-09-0078","article-title":"ABL alternative splicing is quite frequent in normal population.","volume":"9","author":"Santamaria","year":"2010","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"2019111808145209200_B25","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1158\/1535-7163.MCT-10-0311","article-title":"Variant isoforms of BCR-ABL1 in chronic myelogenous leukemia reflect alternative splicing of ABL1 in normal tissue.","volume":"9","author":"Khorashad","year":"2010","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"2019111808145209200_B26","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1158\/1535-7163.MCT-10-0595","article-title":"Exon 7 deletion in the bcr-abl gene is frequent in chronic myeloid leukemia patients and is not correlated with resistance against imatinib.","volume":"9","author":"Gaillard","year":"2010","journal-title":"Mol Cancer Ther"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/19\/5250\/1344636\/zh804511005250.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/19\/5250\/1344636\/zh804511005250.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T13:35:32Z","timestamp":1574084132000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/19\/5250\/29351\/The-BCRABL35INS-insertiontruncation-mutant-is"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,10]]},"references-count":26,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2011,11,10]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-05-349191","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,10]]}}}